PepGen Inc. Reports Q2 2026 Results; Advances PGN‑EDODM1 to Highest Dose

What Happened
On August 6, 2026, PepGen Inc. announced its financial results for the quarter ended June 30, 2026 and furnished a press release and updated corporate materials. The company also disclosed that an independent Data and Safety Monitoring Board (DSMB) recommended advancing the ongoing Phase 2 FREEDOM2‑DM1 study into the third and highest multiple ascending dose (MAD) cohort at 12.5 mg/kg, with no recommended changes to the study protocol. The DSMB further recommended dose escalation in the open‑label extension (OLE) from 5 mg/kg to 10 mg/kg. Press releases and the updated corporate presentation were furnished as Exhibits 99.1–99.3 to the Form 8‑K. The filing is signed by CFO Noel Donnelly.

Key Details

• Filing date: August 6, 2026; quarter reported: ended June 30, 2026.
• DSMB recommendation: advance FREEDOM2‑DM1 into MAD cohort at 12.5 mg/kg; no protocol changes recommended.
• OLE dose change: DSMB recommended escalation from 5 mg/kg to 10 mg/kg.
• Corporate materials: press release on Q2 results (Exhibit 99.1), updated corporate presentation (Exhibit 99.2), and DSMB advancement press release (Exhibit 99.3).

Why It Matters

• Clinical progress: A DSMB nod to advance to the highest MAD cohort and to increase OLE dosing are concrete trial‑development milestones that show the program is proceeding on the planned path without safety‑related protocol changes.
• Investor action: The 8‑K signals both operational (clinical) progress and updated quarterly results — investors should review the furnished press release and presentation (Exhibits 99.1–99.3) for financial details (revenue, cash runway, guidance) and for management commentary on next steps.
• Risk reminder: The filing reports progress and materials but does not change prior disclosures about the investigational nature of PGN‑EDODM1 or guarantee clinical or commercial success.